Recombinant Human Angiopoietin-like 4, His-tagged
Cat.No. : | ANGPTL4-118H |
Product Overview : | Recombinant Human ANGPTL4 produced inE.coliis manufactured with N-terminal fusion of His Tag. The Angiopoietin-like Protein 4 His-Tagged Fusion Protein is 25 kDa protein containing 204 amino acid residues of the Angiopoietin-like Protein 4 and 16 additional amino acid residues - His Tag. |
- Specification
- Gene Information
- Related Products
Cat. No. : | ANGPTL4-118H |
Description : | The fasting-induced adipose factor (FIAF, ANGPTL4, PGAR, HFARP) was identified as an adipocytokine up-regulated by fasting, by peroxisome proliferator-activated receptor agonists, and by hypoxia. At the protein level, in human and mouse blood plasma, FIAF was found to be present both as a native protein and in a truncated form. Differentiation of mouse 3T3-L1 adipocytes was associated with the production of truncated FIAF, whereas in human white adipose tissue and SGBS adipocytes, only the native FIAF could be detected. Interestingly, the truncated FIAF was produced by human liver. Experimental data suggest that FIAF is mainly presented in human blood plasma in a truncated form (FIAF-S2), whose level is increased by fenofibrate treatment. Levels of both truncated and native FIAF showed marked inter individual variation but were not associated with body mass index and were not influenced by prolonged semistarvation. |
Source : | Escherichia Coli. |
Amino Acid Sequence : | MRGSHHHHHH GMASHMGPVQ SKSPRFASWD EMNVLAHGLL QLGQGLREHA ERTRSQLSAL ERRLSACGSA CQGTEGSTDL PLAPESRVDP EVLHSLQTQL KAQNSRIQQL FHKVAQQQRH LEKQHLRIQH LQSQFGLLDH KHLDHEVAKP ARRKRLPEMA QPVDPAHNVS RLHRLPRDCQ ELFQVGERQS GLFEIQPQGS PPFLVNCKMT SDGGWTVIQR |
Specificity : | The amino acid sequence of the recombinant Human Angiopoietin-like Protein 4 is 100% homologous to the 26-229 amino acid sequence of the Angiopoietin-like Protein-4 precursor without signal sequence. |
Purification Method : | One-step procedure using affinity Ni-NTA chromatography. |
Purity : | Greater than 95% as determined by SDS-PAGE. |
Formulation : | Sterile filtered and lyophilized from 0.5 mg/ml in 0.05M Acetate buffer pH-4. |
Solubility : | Add 0.2 ml of 0.1M Acetate buffer pH4 and let the lyophilized pellet dissolve completely. For conversion into higher pH value, we recommend intensive dilution by relevant buffer to a concentration of 10μg/ml. In higher concentrations the solubility of this antigen is limited. |
Biological Activity : | The biological activity was determined by the induction of endothelial cell sprouting as described in Korff et al., 2001. |
Protein Content : | Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm using the absorbency value of 1.4 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of ANG-2 as a Reference Standard. |
Applications : | Western blotting, ELISA. |
Storage : | Store lyophilized Angiopoietin-like Protein 4 at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C. The lyophilized protein remains stable until the expiry date when stored at -20°C. |
Gene Name : | ANGPTL4 angiopoietin-like 4 [ Homo sapiens ] |
Synonyms : | ANGPTL4; angiopoietin-like 4; NL2; ARP4; FIAF; PGAR; HFARP; pp1158; ANGPTL2; fasting-induced adipose factor; PPARG angiopoietin related protein; hepatic angiopoietin-related protein; hepatic fibrinogen/angiopoietin-related protein; peroxisome proliferator-activated receptor (PPAR) gamma; induced angiopoietin-related protein; angiopoietin-related protein 4; PSEC0166, UNQ171/PRO197 |
Gene ID : | 51129 |
mRNA Refseq : | NM_001039667 |
Protein Refseq : | NP_001034756 |
MIM : | 605910 |
UniProt ID : | Q9BY76 |
Chromosome Location : | 19p13.3 |
Pathway : | PPAR signaling pathway; Metabolism of lipids and lipoproteins |
Function : | enzyme inhibitor activity; receptor binding |
Products Types
◆ Recombinant Protein | ||
ANGPTL4-091H | Recombinant Human ANGPTL4 Protein, His-tagged | +Inquiry |
ANGPTL4-102H | Recombinant Human ANGPTL4 Protein, FLAG-tagged | +Inquiry |
ANGPTL4-326R | Recombinant Rat ANGPTL4 Protein, His (Fc)-Avi-tagged | +Inquiry |
Angptl4-153M | Recombinant Mouse Angptl4 Protein, His-tagged | +Inquiry |
ANGPTL4-2470H | Recombinant Human ANGPTL4 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
ANGPTL4-746MCL | Recombinant Mouse ANGPTL4 cell lysate | +Inquiry |
ANGPTL4-1097HCL | Recombinant Human ANGPTL4 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (12)
Ask a questionYes, ANGPTL4 is considered a potential target for drug development. Inhibitors of ANGPTL4 have shown promise in preclinical studies for the treatment of lipid disorders, as they can increase lipoprotein lipase activity and reduce circulating triglyceride levels. Additionally, targeting ANGPTL4 in cancer therapy is being explored due to its involvement in tumor growth and metastasis. However, further research is needed to develop safe and effective drugs targeting ANGPTL4.
Yes, ANGPTL4 protein has been explored as a potential biomarker in various diseases. Increased circulating levels of ANGPTL4 have been associated with obesity, insulin resistance, and metabolic disorders. ANGPTL4 levels have also been correlated with adverse lipid profiles and cardiovascular diseases. In cancer, ANGPTL4 expression and secretion have been linked to tumor progression and metastasis. However, further research is needed to determine the exact utility and significance of ANGPTL4 as a biomarker in different clinical settings.
Yes, there are known mutations and polymorphisms in the ANGPTL4 gene that can affect its function. One well-studied mutation is the E40K variant, which results in a change in the amino acid at position 40 from glutamic acid (E) to lysine (K). This mutation leads to increased ANGPTL4 activity and is associated with lower levels of triglycerides and higher levels of high-density lipoprotein (HDL) cholesterol in the blood. Another variant, T266M, has also been identified and is associated with alterations in lipid metabolism. These genetic variations highlight the potential impact of ANGPTL4 gene mutations on metabolic traits.
Yes, ANGPTL4 can affect other metabolic pathways beyond lipid metabolism. Apart from its well-established role in lipid metabolism, ANGPTL4 has been shown to regulate glucose metabolism, insulin sensitivity, and energy expenditure. ANGPTL4 can influence glucose uptake and insulin signaling in adipose tissue and skeletal muscles. It also affects the production and secretion of adipokines, such as adiponectin, which play a role in metabolic processes. ANGPTL4's involvement in various metabolic pathways highlights its complex role in maintaining metabolic homeostasis.
Yes, there is evidence to suggest that ANGPTL4 protein may play a role in appetite regulation. ANGPTL4 has been found to affect the release of gut hormones, such as ghrelin and glucagon-like peptide-1 (GLP-1), which are important regulators of appetite. Additionally, ANGPTL4 can modulate the activity of hypothalamic neurons involved in appetite control. However, the exact mechanisms underlying ANGPTL4's role in appetite regulation are still being investigated.
ANGPTL4 has been implicated in several diseases and disorders. It is associated with obesity, insulin resistance, and metabolic syndrome. Additionally, ANGPTL4 is linked to various cancers, including breast, lung, and colorectal cancer, as it affects tumor growth, metastasis, and angiogenesis. ANGPTL4 is also connected to cardiovascular diseases and atherosclerosis.
Yes, ANGPTL4 can interact with other proteins and molecules. For example, ANGPTL4 has been shown to interact with members of the integrin family, such as integrin alpha V beta 3 and integrin alpha 5. These interactions are important for ANGPTL4's involvement in angiogenesis and cell migration. ANGPTL4 can also interact with lipoprotein lipase (LPL), an enzyme involved in lipid metabolism, and regulate its activity. Additionally, ANGPTL4 can interact with extracellular matrix components, such as heparan sulfate proteoglycans, which can influence its localization and functions. The interactions between ANGPTL4 and other molecules contribute to its diverse biological roles.
Yes, ANGPTL4 has been implicated in wound healing and tissue regeneration processes. ANGPTL4 is involved in angiogenesis, the formation of new blood vessels, which is crucial for wound healing. It promotes the migration and proliferation of endothelial cells, facilitating blood vessel formation. Additionally, ANGPTL4 has been shown to regulate tissue repair and remodeling in various organs, including the liver, skin, and intestines. However, further research is needed to fully understand the extent of ANGPTL4's role in these processes.
Yes, ANGPTL4 has been implicated in the development and progression of several diseases. It has been associated with obesity, insulin resistance, and metabolic disorders, such as type 2 diabetes and dyslipidemia. ANGPTL4 has also been found to play a role in cancer progression and metastasis, particularly in breast cancer and colorectal cancer. Additionally, ANGPTL4 has been linked to cardiovascular diseases, such as atherosclerosis and hypertension. Its involvement in these diseases highlights the multifaceted role of ANGPTL4 in various pathological processes.
Yes, genetic variations in the ANGPTL4 gene have been identified. Certain single nucleotide polymorphisms (SNPs) in the ANGPTL4 gene are associated with altered circulating lipid levels, increased risk of obesity, insulin resistance, and cardiovascular diseases. These variations can impact ANGPTL4 protein expression or function.
Yes, there is ongoing research and clinical trials related to ANGPTL4. Scientists continue to study its role in lipid metabolism, obesity, cancer, and cardiovascular diseases. Clinical trials are investigating the therapeutic potential of targeting ANGPTL4 for the treatment of metabolic disorders and cancer. Monitoring scientific literature and clinical trial databases can provide more specific details about current research in this area.
Yes, there are several drugs and therapeutic interventions that target ANGPTL4. One approach is the use of monoclonal antibodies that specifically bind to ANGPTL4 and inhibit its function. These antibodies have shown promise in reducing triglyceride levels and improving lipid profiles in preclinical studies. Another approach is the development of small molecule inhibitors that can target ANGPTL4 activity. These inhibitors have been shown to attenuate angiogenesis and tumor growth in cancer models. However, it is important to note that these interventions are still in the early stages of development and further research is needed before they can be used in clinical settings.
Customer Reviews (5)
Write a reviewTheir team of experts possesses an in-depth understanding of the protein and its applications, which proves instrumental in troubleshooting and optimizing experimental protocols.
the manufacturer's customer-centric approach highlights their focus on ensuring my satisfaction.
This commitment ensures that I have access to the most advanced and reliable protein available, enhancing the integrity and impact of my experiments.
The manufacturer's responsive and knowledgeable support system promptly addresses any questions or concerns I may have, greatly streamlining my research process.
the manufacturer's dedication to innovation and continuous improvement stands out.
Ask a Question for All ANGPTL4 Products
Required fields are marked with *
My Review for All ANGPTL4 Products
Required fields are marked with *
Inquiry Basket